Treatments for Brain Metastases With Poor Prognostic Factors

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about treatments in brain metastases with poor prognostic factors. The main questions it aims to answer are: What kind of local treatment provides a survival benefit for patients with poor prognostic factors? What kind of systemic treatment provides a survival benefit for patients with poor prognostic factors? Will the combination of local treatment and systemic treatment provide a survival benefit for patients with poor prognostic factors? Participants will be asked to provide personal information about their living status, symptoms, and disease control during the follow-up.

Official Title
-----------------
Effects of Local and Systemic Treatments in Brain Metastases With Poor Prognostic Factors: Multicenter Retrospective Study

Conditions
-----------------
Brain Metastases

Intervention / Treatment
-----------------
* Procedure: neurosurgical resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Evidence of pathological diagnosis of primary tumor; Brain metastases confirmed by enhanced magnetic resonance imaging; Complete clinical information Exclusion Criteria: Survival time less than 30 days; If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery; Incomplete clinical data; Patients with 2 or more types of tumors.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| local treatment group vs non-local treatment group<br>Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group or otherwise into non-local treatment group | Procedure: neurosurgical resection<br>* neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide<br>* Other names: target therapy;|
| systemic treatment group vs non-systemic treatment group<br>Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group or otherwise into non-systemic treatment group | |
| local treatment group vs systemic treatment group<br>Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group | Procedure: neurosurgical resection<br>* neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide<br>* Other names: target therapy;|
| local treatment group vs local treatment+systemic treatment group<br>Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group | Procedure: neurosurgical resection<br>* neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide<br>* Other names: target therapy;|
| systemic treatment group vs local treatment+systemic treatment group<br>Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group | Procedure: neurosurgical resection<br>* neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide<br>* Other names: target therapy;|
| local treatment+systemic treatment group vs non-local treatment+systemic treatment group<br>Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group or otherwise into non-local treatment+systemic treatment group | Procedure: neurosurgical resection<br>* neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide<br>* Other names: target therapy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | Overall survival time | From date of first follow-up until the date of documented death from any cause, assessed up to 120 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Progression-free survival time | From date of first follow-up until the date of first documented progression, assessed up to 120 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brain Metastases, local treatments, systemic treatments, poor prognosis